InvestorsHub Logo
Followers 0
Posts 1474
Boards Moderated 0
Alias Born 02/10/2022

Re: TheFinalCD post# 6

Sunday, 03/06/2022 11:05:17 AM

Sunday, March 06, 2022 11:05:17 AM

Post# of 119
Likely very wrong, S-M.:

“Among participants with evaluable baseline tumor biopsies, tumor burden reduction was achieved exclusively in those with high ATRC-101 target expression.”

"Pantginis concluded, reiterating the Buy rating and the $25 per share target on the stock."

https://seekingalpha.com/news/3809653-atreca-spikes-as-hc-wainwright-welcomes-updated-cancer-drug-data

https://pulse2.com/atreca-bcel-stock-why-the-price-is-much-higher-today/

https://www.marketbeat.com/instant-alerts/nasdaq-bcel-options-data-report-2022-03/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BCEL News